RFL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 21:06):

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel...

Stats
Dagens volum	15 210.00
Gjennomsnittsvolum	23 488.00
Markedsverdi	40.57M
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $0 ) 2024-06-11
Last Dividend	$0.0200 ( 2009-12-18 )
Next Dividend	$0 ( N/A )
P/E	17.05
ATR14	$0.0220 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share
2024-04-04	Jonas Howard S	Sell	348 259	Class B Common Stock, par value $.01 per share
2024-03-21	Conkling William	Buy	15 473	Class B Common Stock, par value $.01 per share
2024-03-21	Polinsky David	Sell	2 300	Class B Common Stock, par value $.01 per share
2024-01-30	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share

INSIDER POWER
52.49
Last 99 transactions
Buy: 18 593 840 \| Sell: 14 829 947

Rafael Holdings Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Rafael Holdings Inc Økonomi

Annual	2023
Omsetning:	$279 000
Bruttogevinst:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2023
Omsetning:	$279 000
Bruttogevinst:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2022
Omsetning:	$410 000
Bruttogevinst:	$338 000 (82.44 %)
EPS:	$-6.31

FY	2021
Omsetning:	$3.97M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Rafael Holdings Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Rafael Holdings Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.90 - low (62.71%) | Divividend Growth Potential Score: 0.471 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2009-06-19
Last Dividend	$0.0200	2009-12-18
Next Dividend	$0	N/A
Payout Date	2009-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.0400	--
Avg. Dividend % Per Year	0.00%	--
Score	1.83	--
Div. Sustainability Score	4.90
Div.Growth Potential Score	0.471
Div. Directional Score	2.69	--

Next Divdend (Est)
(2024-10-14)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.83

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	7.77	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0201	1.200	9.33	10.00	[0 - 0.3]
returnOnEquityTTM	0.0213	1.500	-0.875	-1.312	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	23.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	22.86	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.19	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0160	-1.500	9.73	-10.00	[0 - 0.6]
interestCoverageTTM	-7.98	1.000	-4.07	-4.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
freeCashFlowPerShareTTM	1.775	2.00	9.11	10.00	[0 - 20]
debtEquityRatioTTM	0.0162	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.665	1.000	2.24	2.24	[0.2 - 0.8]
operatingProfitMarginTTM	-40.96	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.37	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00259	0.800	-3.32	-2.65	[0.5 - 2]
Total Score				4.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.85	1.000	8.20	0	[1 - 100]
returnOnEquityTTM	0.0213	2.50	-0.562	-1.312	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.775	2.00	9.41	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.313	1.500	-1.246	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-27.00	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.471

Rafael Holdings Inc

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.